Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
Completed · Phase 3 · NCT06572449
Conditions: Schizophrenia
At a glance
- Research payments reported, 2025
- $19.6M
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 173
About the trial
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Tested
- KarXT (drug)
- Dates
- Started 2024-10-28; completion 2025-03-13
- Results posted
- Yes
The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
From ClinicalTrials.gov, last updated 2026-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $19.6M in research payments for this study in 2025 (4 payments).
Products named: Cobenfy
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Evagelos Coskinas, M.D. Psychiatry · Costa Mesa, CA
- Edwin A. Gomez, M.D. Psychiatry · Weston, FL
- Kimball A. Johnson, MD Internal Medicine · Atlanta, GA
- Elyssa L. Barron, M.D. Psychiatry · White Plains, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Research Centers of America $5.3M
- Cenexel Iresearch Atlanta $5.1M
- Cenexel Atlanta $4.9M
- Cenexel Cit $4.3M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.